

Remarks


Claims 1-13 are pending in the application. Claims 10-13 have been amended to correct various informalities. No new matter has been added. An Appendix showing claim amendments follows.

Applicants submit that the application is in condition for allowance and such action is respectfully requested.

Should any questions or issues arise concerning the application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

The Commissioner is hereby authorized to charge payment of any fees required in connection with the papers transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 22058-513CON).

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
David E. Johnson, Reg. No. 41,874
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Appendix

10. (Amended) The method of claim 8, wherein the gastrointestinal disorder is selected from the group consisting of: [gastrointestinal] gastroesophageal reflux [disease] disease, post-operative adynamic ileus and intolerance to oral feeding.

11. (Amended) A method of increasing the plasma concentration of motilin in the duodenal mucosa of a mammal which comprises administering to [themammal] the mammal a therapeutically effective amount of [interleukin-11] interleukin-11.

12. (Amended) A method of increasing the tissue concentration of motilin in the duodenal mucosa of a mammal which comprises administering to [themammal] the mammal a therapeutically effective amount of interleukin-11.

13. (Amended) A method of improving the contractile parameters of the neuromuscular gut wall of a mammal afflicted [with] with colitis which comprises administering to [themammal] the mammal a therapeutically effective amount of interleukin-11.

TRADOCS:1426544.5(%kq805!.DOC)

TRA 1745457v1